obstructive sleep apnea, FDA

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
Eli Lilly’s weight-loss drug tirzepatide has become the first drug for obstructive sleep apnea, a common but serious sleep ...
Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on December 9.Don't Miss Our ...
Sleep apnea can significantly increase health risks ... The drug's active ingredient, tirzepatide, is marketed as Zepbound for weight loss and Mounjaro as a diabetes treatment. Zepbound's side ...